Skip to content

Construction of a decision-making aid tool for venous access in colorectal cancer patients

Construction of a decision-making aid tool for venous access in colorectal cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120214
Enrollment
Unknown
Registered
2026-03-11
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Patient group:None

Sponsors

Meishan City Peoples Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient: 1. Age >=18 years old; 2. Colorectal cancer was diagnosed according to the diagnostic criteria of Chinese Society of Clinical Oncology (CSCO); 3. Receiving or planning to receive intravenous access therapy (such as chemotherapy, nutritional support, etc.); 4. Those who participate in the decision-making process of their own venous access; 5. Informed consent and voluntary participation in this study. Medical Staff: 1. Doctors, nurses, or specialized nurses in the fields of oncology, intravenous therapy, or related areas; 2. Relevant field work experience of at least 5 years; 3. Bachelor degree or above; 4. Informed consent and voluntary participation in this study.

Exclusion criteria

Exclusion criteria: Patient: 1. Combined with other serious diseases, which seriously affect their language and cognition; 2. Participate with other investigators. Medical Staff: 1. Dropouts due to various reasons; 2. Participate in other investigators.

Design outcomes

Primary

MeasureTime frame
Degree of coordination of expert opinions;Expert authority coefficient;

Countries

China

Contacts

Public ContactXin Jian

Meishan City Peoples Hospital

jianxin12055@qq.com+86 28 3822 0813

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026